» Articles » PMID: 34784029

Application of Reverse Vaccinology and Immunoinformatic Strategies for the Identification of Vaccine Candidates Against Shigella Flexneri

Overview
Specialty Molecular Biology
Date 2021 Nov 16
PMID 34784029
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Reverse vaccinology (RV) was first introduced by Rappuoli for the development of an effective vaccine against serogroup B Neisseria meningitidis (MenB). With the advances in next generation sequencing technologies, the amount of genomic data has risen exponentially. Since then, the RV approach has widely been used to discover potential vaccine protein targets by screening whole genome sequences of pathogens using a combination of sophisticated computational algorithms and bioinformatic tools. In contrast to conventional vaccine development strategies, RV offers a novel method to facilitate rapid vaccine design and reduces reliance on the traditional, relatively tedious, and labor-intensive approach based on Pasteur"s principles of isolating, inactivating, and injecting the causative agent of an infectious disease. Advances in biocomputational techniques have remarkably increased the significance for the rapid identification of the proteins that are secreted or expressed on the surface of pathogens. Immunogenic proteins which are able to induce the immune response in the hosts can be predicted based on the immune epitopes present within the protein sequence. To date, RV has successfully been applied to develop vaccines against a variety of infectious pathogens. In this chapter, we apply a pipeline of bioinformatic programs for identification of Shigella flexneri potential vaccine candidates as an illustration immunoinformatic tools available for RV.

Citing Articles

Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance.

La Guidara C, Adamo R, Sala C, Micoli F Int J Mol Sci. 2024; 25(10).

PMID: 38791526 PMC: 11122364. DOI: 10.3390/ijms25105487.


Bioinformatics and immunoinformatics assisted multiepitope vaccine construct against .

Alshiekheid M, Dou A, Algahtani M, Al-Megrin W, Alhawday Y, Alradhi A Saudi Pharm J. 2024; 32(1):101917.

PMID: 38226347 PMC: 10788630. DOI: 10.1016/j.jsps.2023.101917.


Designing of a Novel Multi-Antigenic Epitope-Based Vaccine against : An Intergraded Reverse Vaccinology and Immunoinformatics Approach.

Albekairi T, Alshammari A, Alharbi M, Alshammary A, Tahir Ul Qamar M, Ullah A Vaccines (Basel). 2022; 10(5).

PMID: 35632421 PMC: 9143018. DOI: 10.3390/vaccines10050665.

References
1.
Kotloff K, Riddle M, Platts-Mills J, Pavlinac P, Zaidi A . Shigellosis. Lancet. 2017; 391(10122):801-812. DOI: 10.1016/S0140-6736(17)33296-8. View

2.
Banga Singh K, Ojha S, Deris Z, Rahman R . A 9-year study of shigellosis in Northeast Malaysia: Antimicrobial susceptibility and shifting species dominance. Z Gesundh Wiss. 2011; 19(3):231-236. PMC: 3089725. DOI: 10.1007/s10389-010-0384-0. View

3.
Ashkenazi S, Cohen D . An update on vaccines against Shigella. Ther Adv Vaccines. 2014; 1(3):113-23. PMC: 3967666. DOI: 10.1177/2051013613500428. View

4.
Pizza M, Scarlato V, Masignani V, Giuliani M, Arico B, Comanducci M . Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000; 287(5459):1816-20. DOI: 10.1126/science.287.5459.1816. View

5.
Mamede L, de Paula K, de Oliveira B, Dos Santos J, Cunha L, Comar Junior M . Reverse and structural vaccinology approach to design a highly immunogenic multi-epitope subunit vaccine against Streptococcus pneumoniae infection. Infect Genet Evol. 2020; 85:104473. DOI: 10.1016/j.meegid.2020.104473. View